|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.
|
31139940 |
2020 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Expression of biomarkers in the AKT pathway correlates with malignancy and recurrence in phyllodes tumours of the breast.
|
30383904 |
2019 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This bifurcation of signaling complexes from distinct ShcA pools transduces non-redundant signals that integrate the AKT/mTOR and SFK pathways to cooperatively increase breast tumor growth and resistance to tyrosine kinase inhibitors, including lapatinib and PP2.
|
29453318 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Together, this study demonstrates two previously uncharacterized factors AK023948 and DHX9 as important players in the AKT pathway, and that their upregulation may contribute to breast tumour progression.
|
28176758 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Similar results were also seen between liver metastases and primary breast tumors [AKT (S473) <i>P</i> < 0.01, mTOR (S2448) <i>P</i> < 0.01, 4EBP1 (S65) <i>P</i> = 0.01].
|
28446508 |
2017 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Application of these signatures to breast tumor gene expression data identified two novel discrete phenotypes characterized by concordant, aberrant activation of either the HER2, IGF1R, and AKT pathways ("the survival phenotype") or the EGFR, KRAS (G12V), RAF1, and BAD pathways ("the growth phenotype").
|
28446242 |
2017 |
|
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
By using PCR target sequence enrichment and next-generation sequencing technology, we sequenced AKT1 promoter region in pairs of breast tumor and normal tissues from 95 unselected Chinese breast cancer patients.
|
28301567 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2 overexpression and an activated status of AKT and MAPK.
|
25961924 |
2016 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These studies elucidate a new layer of regulation in the PI3K/AKT/mTOR pathway with relevance to mammary development and tumour progression and identify miR-184 as a putative breast tumour suppressor.
|
26070602 |
2015 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibiting AKT or preventing SIRT6 phosphorylation by mutating Ser(338) prevented the degradation of SIRT6 mediated by MDM2, suppressed the proliferation of breast cancer cells in culture, and inhibited the growth of breast tumor xenografts in mice.
|
25074979 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
AKT isoform specific in vitro kinase assays revealed that AKT3 is activated in Balb-neuT breast tumors in comparison to normal murine breast tissue.
|
24463007 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings suggest N-cadherin/FGFR has a pivotal role in promoting metastasis through differential regulation of ERK and AKT, and underscore the potential for targeting the FGFR in advanced ErbB2-amplified breast tumors.
|
23975425 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In summary, the MMTVmyr-Akt1 transgenic mouse model could be useful to study mechanisms of ER-positive breast tumor development.
|
24742286 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, inhibitors to the AKT/IGF-1R signaling pathways may provide alternative approaches to block escape pathways and restore hormone sensitivity in resistant breast tumors.
|
25178514 |
2014 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
For example, although signaling and metabolic profiles of breast tumors with PIK3CA or AKT1 mutations are, as expected, highly similar, they display markedly different, sometimes even opposite, profiles to those with ERBB2 or EGFR amplifications.
|
24166508 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of EXO1 module was found as indicative of elevated cell proliferation, genomic instability, activated RAS/AKT/MYC/E2F1 signaling pathways and loss of p53 activity in breast tumors. mRNA-drug connectivity analysis indicates inhibition of RAS/PI3K as a possible targeted therapeutic approach for the patients with activated EXO1 module in breast tumors.
|
24147022 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In this report, we provide evidence that VAPB regulates breast tumor cell proliferation and AKT activation.
|
23049696 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, five genes frequently mutated in breast cancers: TP53, PIK3CA, PTEN, CDH1, and AKT1 were screened in each of 120 human primary breast tumors.
|
21512767 |
2012 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The activation of the oncogene PIK3CA and the loss of regulators of AKT including the tumor suppressor gene PTEN are mutations commonly found in breast tumors.
|
21406469 |
2011 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Available paired tissue samples from breast tumors known to harbor mutations underwent massARRAY genotyping (n = 70) to identify PIK3CA and AKT1(E17K) mutations.
|
21617917 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Estrogens induce breast tumor cell proliferation by directly regulating gene expression via the estrogen receptor (ER) transcriptional activity and by affecting growth factor signaling pathways such as mitogen-activated protein kinase (MAPK) and AKT/mammalian target of rapamycin Complex1 (mTORC1) cascades.
|
20054642 |
2010 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These data suggest that activation of the ERBB2-PI3K-AKT pathway by loss of PTEN at early stages of tumorigenesis promotes the formation of breast tumors with apocrine features.
|
20712882 |
2010 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To identify relevant downstream target genes and signaling activated by aberrant PI3K/AKT pathway in breast tumors, we first analyzed gene expression with a pangenomic oligonucleotide microarray in a series of 43 ERα-positive tumors with and without PIK3CA mutations.
|
21209903 |
2010 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.
|
20228224 |
2010 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, here we show through phosphoprotein profiling and functional genomic studies that many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth.
|
19573809 |
2009 |